Please login to the form below

Not currently logged in
Email:
Password:

Active Biotech

This page shows the latest Active Biotech news and features for those working in and with pharma, biotech and healthcare.

Teva drops laquinimod for most common form of MS after failed trial

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo. Teva and Active Biotech have suffered another setback in their efforts to develop laquinimod for multiple sclerosis and are abandoning the programme. ... Shares in Active Biotech

Latest news

  • Another setback for Teva's laquinimod in MS Another setback for Teva's laquinimod in MS

    Teva and partner Active Biotech have said they will continue to develop multiple sclerosis (MS) candidate laquinimod, despite side effects seen in two late-stage trials. ... Teva and Active Biotech have been through the mill trying to bring laquinimod to

  • MS market set to grow 4% annually

    When it comes to branded medicines, Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063 are the projected

  • Teva backs laquinimod for MS despite CHMP rejection Teva backs laquinimod for MS despite CHMP rejection

    EMA confirms negative opinion after re-examination. Teva and partner Active Biotech have vowed to continue developing laquinimod as an oral therapy for multiple sclerosis (MS), despite being rejected for approval ... Teva and Active Biotech still feel

  • CHMP turns down drugs for MS, cancer and muscular dystrophy CHMP turns down drugs for MS, cancer and muscular dystrophy

    In Teva's response to the decision, the Israeli company said it and partner Active Biotech were committed to the development of laquinimod as a treatment for MS and will request

  • Czech biotech Sotio selects Chiltern International

    UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials. ... The trials will assist the biotech company's development of Active Cellular Immunotherapy

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    100. Active Biotech (SE). NeoTx (IS). Licence. Tumour Targeting Superantigen ANYARA in phase I for oncology.

  • Pharma deals during December 2012 Pharma deals during December 2012

    European biotech also active. Not all the drug discovery action is in Texas or California, as Evotec (based in Germany) has ably demonstrated this year. The licensing deal in December with ... Another deal involving European biotech companies is the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics